ClinicalTrials.gg
RecruitingNCT05943522Updated Apr 20, 2026

Asciminib RMP Study

An observational study in Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Recruiting at 17 sites in South Korea. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
600
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis — 9 open to participants now, 13 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Novartis.

Planned enrollment
6th of 19
600 · median 400
Started
2023
with 1 other
Observational
19 of 92
6 open now
Primary completion
2030-06
later than 9 of 12 live
Registered
77th of 92
by date

Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 6th largest by planned enrollment of the 19 observational ones that give a count, is one of 2 that started in 2023, is one of 19 observational ones, reaches primary completion later than 9 of the 12 other live ones, and was the 77th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

9 of the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, or all of them as a file.
02

Study summary

This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.

Read the detailed description

The dosage and duration of treatment may be considered and decided by the investigator in accordance with prescribing information of Asciminib.

This study will enroll all patients by total enumeration for those prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice for 2 years after the market launch.

03

Conditions studied

  • Chronic Myeloid Leukemia

Keywords

  • Scemblix
  • Asciminib
  • CML
  • Chronic Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who are going to receive Scemblix® for the first time or those who are currently taking Scemblix® per clinical judgment are eligible and will be prescribed with Scemblix® under routine medical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label
  2. Patients who are willing to provide written prior to study enrollment

Exclusion criteria

Exclusion criteria

  1. Patients with according to locally approved label of Scemblix®
  2. Patients who receive or are going to receive any medicine during the observation period
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Asciminib

    Patients prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice

    Other: Asciminib

Interventions

  • OtherAsciminib

    There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis

    Also known as: Scemblix

06

What researchers measure

Primary outcomes

  1. Percentage of participants with an AE / ADR

    Percentage of participants with an adverse event (AE)/ adverse drug reaction (ADR)

    Time frame: 24 weeks

  2. Percentage of participants with a SAE / SADR

    Percentage of participants with a serious AE (SAE)/ serious ADR (SADR)

    Time frame: 24 weeks

  3. Percentage of participants with an UAE/ UADR

    Percentage of participants with an unexpected AE (UAE)/ unexpected ADR (UADR)

    Time frame: 24 weeks

  4. Percentage of participants with a SUAE/ SUADR

    Percentage of participants with a serious unexpected AE (SUAE)/ serious unexpected ADR (SUADR)

    Time frame: 24 weeks

Secondary outcomes

  1. Major molecular response rate

    Major molecular response (MMR) rate at week 12 and week 24

    Time frame: week 12, week 24

  2. Molecular response 4 rate

    Molecular response 4 (MR4) rate. Molecular response (MR) is a Breakpoint Cluster Region protein Tyrosine-protein kinase ABL1 (BCR-ABL1) transcript that is assessed by real-time quantitative PCR (RQ-PCR) in the blood at screening. Molecular response levels are indicated with a superscript indicating the log reduction from the standardized baseline, corresponding to 100% on the international scale (IS).

    Time frame: week 12, week 24

  3. Molecular response 4.5 rate

    Molecular response 4.5 (MR4.5) rate. Molecular response (MR) is a Breakpoint Cluster Region protein Tyrosine-protein kinase ABL1 (BCR-ABL1) transcript that is assessed by real-time quantitative PCR (RQ-PCR) in the blood at screening. Molecular response levels are indicated with a superscript indicating the log reduction from the standardized baseline, corresponding to 100% on the international scale (IS).

    Time frame: week 12 ,week 24

  4. Number of participants with CCyR and/or BCR-ABL1 IS<1%

    Complete cytogenetic response (CCyR) rate and/or BCR-ABL1 IS\<1%. A complete cytogenetic response (CCyR) is defined as absence of the Ph (0%) among at least 20 cells in metaphase in a bone marrow aspirate.

    Time frame: week 12,week 24

07

Study locations

17 of 17 sites recruiting
  • Novartis Investigative Site
    Wŏnju, Gangwon-do 26426, South Korea
    Recruiting
  • Novartis Investigative Site
    Anyang-si, Gyeonggi-do 14068, South Korea
    Recruiting
  • Novartis Investigative Site
    Bucheon-si, Gyeonggi-do 14584, South Korea
    Recruiting
  • Novartis Investigative Site
    Uijeongbu-si, Gyeonggi-do 11759, South Korea
    Recruiting
  • Novartis Investigative Site
    Gyeonggi-do, Korea 10408, South Korea
    Recruiting
  • Novartis Investigative Site
    Incheon, Korea 405 760, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, Korea 02841, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, Seoul 03080, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, Seoul 06351, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, Yangcheon gu 07985, South Korea
    Recruiting
  • Novartis Investigative Site
    Suwon, Yeongtong Gu 16499, South Korea
    Recruiting
  • Novartis Investigative Site
    Jeollanam, 519763, South Korea
    Recruiting
  • Novartis Investigative Site
    Pusan, 614 735, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 03722, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 05505, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 06591, South Korea
    Recruiting
  • Novartis Investigative Site
    Taegu, 41944, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jun 2030, 82 months after the start.

Of 67 observational studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 82 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Jul 13, 2023
StartActual
Jul 19, 2023
Primary completionEst.
Jun 7, 2030
CompletionEst.
Jun 7, 2030
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05943522
Responsible party
Sponsor
First posted
Jul 13, 2023
Start date
Jul 19, 2023
Primary completion
Jun 7, 2030 (estimated)
Completion
Jun 7, 2030 (estimated)
Last update
Apr 20, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion